Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) Insider Martin J. Driscoll Buys 10,000 Shares

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) insider Martin J. Driscoll acquired 10,000 shares of the stock in a transaction dated Tuesday, April 30th. The stock was bought at an average price of $7.34 per share, for a total transaction of $73,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Spring Bank Pharmaceuticals stock opened at $6.92 on Friday. The stock has a market cap of $116.42 million, a PE ratio of -3.70 and a beta of 0.53. Spring Bank Pharmaceuticals Inc has a 1 year low of $6.30 and a 1 year high of $15.00.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Monday, April 29th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.20. Equities research analysts predict that Spring Bank Pharmaceuticals Inc will post -2.27 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of SBPH. BNP Paribas Arbitrage SA grew its position in shares of Spring Bank Pharmaceuticals by 1,395.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,946 shares of the company’s stock valued at $31,000 after purchasing an additional 2,749 shares during the period. JPMorgan Chase & Co. boosted its position in Spring Bank Pharmaceuticals by 464.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock worth $153,000 after acquiring an additional 10,458 shares during the last quarter. Rhumbline Advisers boosted its position in Spring Bank Pharmaceuticals by 65.3% during the 4th quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock worth $174,000 after acquiring an additional 6,623 shares during the last quarter. Pegasus Asset Management Inc. acquired a new position in Spring Bank Pharmaceuticals during the 4th quarter worth approximately $195,000. Finally, State of Wisconsin Investment Board boosted its position in Spring Bank Pharmaceuticals by 30.3% during the 1st quarter. State of Wisconsin Investment Board now owns 18,900 shares of the company’s stock worth $198,000 after acquiring an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 43.08% of the company’s stock.

Several equities research analysts have recently issued reports on SBPH shares. ValuEngine downgraded shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Zacks Investment Research downgraded shares of Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Cantor Fitzgerald set a $29.00 price target on shares of Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 12th. Chardan Capital set a $25.00 price objective on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, April 12th. Finally, Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, May 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Spring Bank Pharmaceuticals has an average rating of “Buy” and an average price target of $23.80.

COPYRIGHT VIOLATION NOTICE: “Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) Insider Martin J. Driscoll Buys 10,000 Shares” was posted by Mayfield Recorder and is the property of of Mayfield Recorder. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://mayfieldrecorder.com/2019/05/18/spring-bank-pharmaceuticals-inc-sbph-insider-purchases-73400-00-in-stock.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Recommended Story: P/E Growth (PEG)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.